InnoCan Pharma's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 0.
InnoCan Pharma's Days Inventory for the
three
months ended in Mar. 2026 was 345.72.
InnoCan Pharma's Days Payable for the
three
months ended in Mar. 2026 was 44.59.
Therefore, InnoCan Pharma's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 301.13.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
InnoCan Pharma Cash Conversion Cycle Related Terms
InnoCan Pharma Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INNPF vs PG, CL, KVUE: Cash Conversion Cycle Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Cash Conversion Cycle vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
InnoCan Pharma's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (INNPF) has a Cash Conversion Cycle of 301.13 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's Cash Conversion Cycle too high?
InnoCan Pharma's current Cash Conversion Cycle is 301.13. The Consumer Packaged Goods industry median Cash Conversion Cycle is 75.44. InnoCan Pharma's value of 301.13 is 299.2% above this industry median. Overall, InnoCan Pharma has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Cash Conversion Cycle compare to PG and CL?
InnoCan Pharma's Cash Conversion Cycle of 301.13 can be compared against companies in the Consumer Packaged Goods industry. The industry median Cash Conversion Cycle is 75.44. InnoCan Pharma's value of 301.13 is 299.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Consumer Packaged Goods company?
The median Cash Conversion Cycle among Consumer Packaged Goods companies is 75.44, based on 1,944 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCan Pharma's current Cash Conversion Cycle of 301.13 is 299.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Cash Conversion Cycle is 75.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Cash Conversion Cycle is 301.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (INNPF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.03, compared to a current price of $1.70 — trading 83.1% below its estimated fair value. The current Cash Conversion Cycle is 301.13 and 299.2% above the Consumer Packaged Goods industry median of 75.44. InnoCan Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For InnoCan Pharma (INNPF), the current Cash Conversion Cycle is 301.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (INNPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of $1.70 is trading 83.1% below its estimated GF Value™ of $10.03.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for INNPF:
Cash Conversion Cycle: 301.13
GF Value™: $10.03 vs. price of $1.70 (83.1% below fair value)
Industry Position: 299.2% above the Consumer Packaged Goods median
No single metric tells the full story. See the INNPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
56GF Score
Get the complete analysis for INNPF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INNPF has been successfully added to your 
